Meristem Therapeutics

France's Meristem Therapeutics, spun out of seed producer Groupe Limagrain, is using transgenic plants to produce commercial quantities of purified protein-based pharmaceuticals. It hopes that the success of its phase II product, lipase, will help convince an as-yet skeptical pharmaceutical industry of the value--both in terms of safety, cost and efficiency--of plant-derived therapeutics.

In 1992, Groupe Limagrain, the world's fourth-largest seed producer, initiated a program to produce recombinant therapeutic proteins from plants. Three years later, Molecular Pharming, as the project was called, produced its first harvest, with the successful expression of human hemoglobin in transgenic tobacco plants. By 1998, the project had progressed far enough for Limagrain (which wanted to focus on its seed producing activities) to spin it off as a fully owned subsidiary, Meristem Therapeutics. The following year, Limagrain freed up Meristem to raise €18.3 million ($16.2 million) in first round funding as an independent biotech.

Transgenic plants are increasingly being used as vehicles to produce recombinant protein-based pharmaceuticals, addressing the growing problem of limited production...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By 

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Business

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By 

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.